| Dr Eric Randall Jones, DO | |
|
1100 S Medical Dr, Mount Pleasant, UT 84647 | |
| (435) 462-3471 | |
| Not Available |
| Full Name | Dr Eric Randall Jones |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 11 Years |
| Location | 1100 S Medical Dr, Mount Pleasant, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770823361 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanpete Valley Hospital - Cah | Mount pleasant, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.
The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a new type of assay based on NanoString's nCounter Analysis System.
People with psoriasis have an increased risk for developing Type 2 diabetes compared with people without the skin condition, suggest results from a systematic review and meta-analysis published in the Archives of Dermatology.
› Verified 6 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.
The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a new type of assay based on NanoString's nCounter Analysis System.
People with psoriasis have an increased risk for developing Type 2 diabetes compared with people without the skin condition, suggest results from a systematic review and meta-analysis published in the Archives of Dermatology.
› Verified 6 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.
The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a new type of assay based on NanoString's nCounter Analysis System.
People with psoriasis have an increased risk for developing Type 2 diabetes compared with people without the skin condition, suggest results from a systematic review and meta-analysis published in the Archives of Dermatology.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric Randall Jones, DO Po Box 27128, Slc, UT 84127-0128 Ph: (435) 462-3471 | Dr Eric Randall Jones, DO 1100 S Medical Dr, Mount Pleasant, UT 84647 Ph: (435) 462-3471 |
News Archive
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.
The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a new type of assay based on NanoString's nCounter Analysis System.
People with psoriasis have an increased risk for developing Type 2 diabetes compared with people without the skin condition, suggest results from a systematic review and meta-analysis published in the Archives of Dermatology.
› Verified 6 days ago